Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...
EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained ...
Bristol Myers Squibb has won European Commission expanded approval of its CAR-T cell therapy Breyanzi in the blood cancer lymphoma.
Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T ...
The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.
BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies and ...
Following an expedited walk along the priority review path, Bristol Myers Squibb has announced that its CAR T cell therapy, Breyanzi (lisocabtagene maraleucel; liso-cel), has been awarded US Food ...
Breyanzi showed significant efficacy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma, achieving primary and secondary endpoints in the TRANSCEND FL trial. Marginal zone lymphoma, a slow ...
Hosted on MSN12mon
Bristol Myers (BMY) Gets FDA Nod for Breyanzi's Label ExpansionBristol Myers Squibb BMY announced that the FDA has granted accelerated approval to chimeric antigen receptor (CAR) T cell therapy, Breyanzi (lisocabtagene maraleucel), for one more indication.
Investing.com -- The European Commission has granted Bristol Myers (NYSE: BMY) Squibb, the biopharmaceutical company based in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results